Biostar Pharm-B (02563) announced interim results
- RevenueRMB36.6M
- Net profitRMB-26.6M
- Profit attributable to ownersRMB-26.6M
- Revenue YoY+147.8%
- Net profit YoY+50.8%
- Depreciation & amortisationHK$10.6M
- Capital expenditureHK$-5.4M
- Interest-bearing debtHK$927,401
Source Biostar Pharm-B



